A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis

Resource Type



Bill and Melinda Gates Foundation [OPP1190749,]


Data collected from participants at during a clinical trial in Hohoe, Ghana where participants are identified by a unique participant ID. There are two datasets. The Safety dataset includes demographics, skin snip results, adverse event results, and ophthalmological data from baseline, day of treatment, Day 1-7, Month 3, Month 12, and Month 18. The Nodulectomy data set contains data pertaining to sectioned nodules read by scientists at 18 months which indicate embryogenesis in female worms, number of male and female worms, and worm calcification.


Communicable Disease, Tropical Medicine, Onchocerciasis, Onchocerca volvulus, Microfilariae, Helminths, Nematoda, Filaricides, Ivermectin, Albendazole, Diethylcarbamazine, Clinical Trial, Ophthalmology, Eye Diseases, Western Africa, Ghana

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Publication Date


Associated Publication

README.txt (95 kB)
Zip file contents



Link to Published Version

Published Version